With the full structure of the Anthrax toxin now known, and the mechanism of infection being worked on, new ways to treat the illness are being worked on both privately and publicly. At the forefront of anthrax vaccination and treatment are the drug companies. Right now there is a vaccination for anthrax that is fairly effective, but it could be much better. Right now the vaccination against anthrax is based around the production of antigens to the PA. This works fairly well to block the ATR, but it has a rather short time in the body. It has been found that the body produces a much more sustained resistance when the LF antigens are produced. These antigens bind to the LF before it is able to make its way to PA and be ingested by the cell (Price et all, 2001). With further work the vaccination to Anthrax could become much safer, much more effective, more available, and more understood.